Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Cybin Inc. is one of them.

Cybin Inc. (NYSE:CYBN) is a clinical-stage neuropsychiatry company developing psychedelic-based treatments for major depressive disorder (MDD) and generalized anxiety disorder (GAD). Its pipeline includes proprietary compounds CYB003, a deuterated psilocin analog, and CYB004, a deuterated N, N-dimethyltryptamine molecule, aimed at providing innovative alternatives for patients with inadequate responses to traditional therapies.

As of August 2025, Cybin Inc. (NYSE:CYBN) has achieved key clinical and regulatory milestones. The company received approvals from European authorities and the UK’s MHRA to initiate EMBRACE, its second pivotal Phase 3 study under the PARADIGM program. EMBRACE will enroll approximately 330 participants across the US, UK, Europe, and Australia to evaluate CYB003 as an adjunctive treatment for moderate to severe MDD over six weeks. Meanwhile, enrollment for the Phase 2 trial of CYB004 in GAD is expected to be completed this month, setting the stage for upcoming data readouts.

Supporting these clinical efforts, Cybin Inc. (NYSE:CYBN) secured up to $500 million in convertible debenture financing from High Trail Special Situations LLC. The funds will accelerate clinical programs, scale up manufacturing, expand intellectual property (over 90 issued patents and 230 pending), and prepare for potential commercialization.

Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy

The business’s strategic momentum highlights its commitment to advancing psychedelic therapeutics for mental health. With multinational trials, robust financing, and promising early data, such as a 71% remission rate in prior CYB003 Phase 2 studies, the company is positioning itself as a leader in next-generation treatments for depression and anxiety. These developments underscore Cybin Inc. (NYSE:CYBN)’s potential to address significant unmet needs and transform neuropsychiatric care with innovative, durable therapies.

While we acknowledge the risk and potential of CYBN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CYBN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.